Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
暂无分享,去创建一个
Geert Molenberghs | Tomasz Burzykowski | Helena Geys | Marc Buyse | Ariel Alonso | Didier Renard | G. Molenberghs | M. Buyse | H. Geys | D. Renard | A. Alonso | T. Burzykowski | Ariel Alonso
[1] P.T.V.M. de Jong,et al. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration , 1997 .
[2] Thomas R. Fleming,et al. Surrogate Endpoints in Clinical Trials , 1996 .
[3] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[4] A. Fielding. Sensitivity Analysis in Linear Regression , 1990 .
[5] S. Ellenberg,et al. Surrogate endpoints in clinical trials: cancer. , 1989, Statistics in medicine.
[6] M Buyse,et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Begg,et al. On the use of surrogate end points in randomized trials , 2000 .
[8] P Bacchetti,et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. , 1991, BMJ.
[9] C. Begg,et al. On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) , 2000 .
[10] Geert Molenberghs,et al. Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes , 2002 .
[11] R J Carroll,et al. On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.
[12] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[13] J. Vermorken. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Dale. Global cross-ratio models for bivariate, discrete, ordered responses. , 1986, Biometrics.
[15] M J Daniels,et al. Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.
[16] G. Batist,et al. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Molenberghs,et al. Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.
[18] Robert Schooley,et al. CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.
[19] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[20] W. Guerra. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .
[21] S. Duffy,et al. Trial Design Based on Surrogate End Points — Application to Comparison of Different Breast Screening Frequencies , 1996 .
[22] S. Weisberg,et al. Residuals and Influence in Regression , 1982 .
[23] N. Nair,et al. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. , 1998, Journal of clinical psychopharmacology.
[24] G. Molenberghs,et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .
[25] Marc Buyse,et al. Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis , 1991 .
[26] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[27] J M Taylor,et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. , 1998, Statistics in medicine.
[28] M S Pepe,et al. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.
[29] S. Chatterjee. Sensitivity analysis in linear regression , 1988 .
[30] V De Gruttola,et al. Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.
[31] Lewis A. Opler,et al. Reliability and validity of the positive and negative syndrome scale for schizophrenics , 1988, Psychiatry Research.